These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27017899)

  • 1. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
    Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
    J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
    Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
    J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination.
    Wieten RW; Jonker EF; van Leeuwen EM; Remmerswaal EB; Ten Berge IJ; de Visser AW; van Genderen PJ; Goorhuis A; Visser LG; Grobusch MP; de Bree GJ
    PLoS One; 2016; 11(3):e0149871. PubMed ID: 26977808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The early cellular signatures of protective immunity induced by live viral vaccination.
    Kohler S; Bethke N; Böthe M; Sommerick S; Frentsch M; Romagnani C; Niedrig M; Thiel A
    Eur J Immunol; 2012 Sep; 42(9):2363-73. PubMed ID: 22733156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
    Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
    Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication.
    Wieten RW; Jonker EF; Pieren DK; Hodiamont CJ; van Thiel PP; van Gorp EC; de Visser AW; Grobusch MP; Visser LG; Goorhuis A
    Vaccine; 2016 Mar; 34(10):1247-51. PubMed ID: 26845742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response.
    Blom K; Braun M; Ivarsson MA; Gonzalez VD; Falconer K; Moll M; Ljunggren HG; Michaëlsson J; Sandberg JK
    J Immunol; 2013 Mar; 190(5):2150-8. PubMed ID: 23338234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.
    James EA; LaFond RE; Gates TJ; Mai DT; Malhotra U; Kwok WW
    J Virol; 2013 Dec; 87(23):12794-804. PubMed ID: 24049183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.
    Campi-Azevedo AC; de Araújo-Porto LP; Luiza-Silva M; Batista MA; Martins MA; Sathler-Avelar R; da Silveira-Lemos D; Camacho LA; de Menezes Martins R; de Lourdes de Sousa Maia M; Farias RH; da Silva Freire M; Galler R; Homma A; Ribeiro JG; Lemos JA; Auxiliadora-Martins M; Caldas IR; Elói-Santos SM; Teixeira-Carvalho A; Martins-Filho OA
    PLoS One; 2012; 7(12):e49828. PubMed ID: 23251351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
    Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
    Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization.
    Co MD; Kilpatrick ED; Rothman AL
    Immunology; 2009 Sep; 128(1 Suppl):e718-27. PubMed ID: 19740333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
    Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
    J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.
    Kongsgaard M; Bassi MR; Rasmussen M; Skjødt K; Thybo S; Gabriel M; Hansen MB; Christensen JP; Thomsen AR; Buus S; Stryhn A
    Sci Rep; 2017 Apr; 7(1):662. PubMed ID: 28386132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T cells complement antibodies in protecting against yellow fever virus.
    Bassi MR; Kongsgaard M; Steffensen MA; Fenger C; Rasmussen M; Skjødt K; Finsen B; Stryhn A; Buus S; Christensen JP; Thomsen AR
    J Immunol; 2015 Feb; 194(3):1141-53. PubMed ID: 25539816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
    Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.
    Kareko BW; Booty BL; Nix CD; Lyski ZL; Slifka MK; Amanna IJ; Messer WB
    J Infect Dis; 2020 Jun; 221(12):2018-2025. PubMed ID: 31545367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
    Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
    Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.